{"disease":{"id":"her2-gene-mutation","name":"her2 gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02993068","title":"Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)","phase":"NA","overall_status":"SUSPENDED","enrollment_count":5200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT05673512","title":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04584255","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06123338","title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT03845270","title":"Her2-positive Lung Cancer Treated With Dedicated Drug","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT06083662","title":"Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false},{"nct_id":"NCT04620187","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06383533","title":"Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05511844","title":"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Orum Therapeutics USA, Inc.","has_results":false},{"nct_id":"NCT07436858","title":"Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT03412383","title":"Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":14,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT02432963","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05054374","title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}